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Abstract 
Adenosine, deriving from ATP released by dying cancer cells and then degradated in the tumor 
environment by CD39/CD73 enzyme axis, is linked to the generation of an immunosuppressed 
niche favoring the onset of neoplasia. The effects of adenosine are mediated by four adenosine 
receptors, named A1, A2A, A2B and A3, that are widely expressed on several immune cell 
populations. A critical role of this nucleoside is emerging in the modulation of myeloid cell subsets 
accumulation and functions into tumor microenvironment, providing new insights that might be 
useful for the development of novel therapeutic approaches aimed to undermine the immune 
privileged sites where cancer cells grow and proliferate. 
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Introduction 
The tumor microenvironment consists of intricate highly complex and dynamic network of cells, 
soluble factors, signaling molecules, extracellular matrix, and mechanical cues deputed to promote 
neoplastic transformation, supporting tumor growth and invasion, shielding the tumor from host 
immunity, fostering therapeutic resistance, and providing niches for thriving of dormant 
metastases.
1
 In this context, the immune cells infiltrating the tumor milieu have gained attention 
since groundswell of evidences highlighted that cancer initiation and progression depend essentially 
on the ability of tumor to escape from host immunosurveillance. 
2
 Indeed, cancer cells put in place a 
variety of molecular tricks to fool the immune system, such as the shift of immune responses, with 
an imbalance in Th1/Th2 responses, and to enhance immunosuppressive cells, such as myeloid-
derived suppressor cells (MDSCs), regulatory T cells, M2 macrophages (tumor-associated 
macrophages), and type 2 natural killer (NK) T cells.
3
 
This body of evidence is revitalizing the interest of the scientific community toward cancer 
immunotherapy as a promising strategy based on the ability to specifically target and destroy tumor 
cells without harming the surrounding normal cells.
4
 In particular, a better understanding of the 
complex molecular mechanisms driving the interplay between immune system and cancer cells has 
led to the identification of several key factors governing these interactions, thus prompting the 
development of 'checkpoint blockades' able to counteract this suppression.
5
 Indeed, over the last 
years we have witnessed the introduction of innovative immunotherapeutic approaches into the 
clinical practice, such as the blockade of immune checkpoints (i.e. CTL4, PD-1 or PDL-1), 
designed to overcome the mechanisms exploited by tumors to elude the immune destruction.
5
 
However, despite immunotherapy is emerging as a viable therapeutic approach to dam the onset and 
progression of different types of cancer, it has become clear that it faces serious barriers that limit 
its clinical efficacy.
6
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Several immunosuppressive pathways and factors, released in the tumor microenvironment, can 
blunt spontaneous or therapeutic immune responses in cancer.
7
 In this context, a plethora of 
research data pointed out the importance of adenosine as a critical regulatory autocrine and 
paracrine factor that accumulates in the neoplastic microenvironment.
8
 
 In the cancer milieu, the dying tumor cells release ATP that participates to the recruitment of 
myeloid and dendritic cells as well as T lymphocytes into the tumor bed 
9, 10
. It is well established 
that some areas of solid tumors often undergo transient or chronic hypoxia, which is conducive to 
extracellular adenosine accumulation, proposed to play a critical role in protecting cancerous tissues 
from antitumor immune responses
11
. However, clear –cut experimental evidences about it are 
needed. Following their release in the tumor microenvironment, ATP and ADP can be converted 
into AMP by CD39, and then CD73 transforms AMP into adenosine (Figure 1). In several cases, 
both CD39 and CD73 are expressed on tumor cells and/or tumor-infiltrating immune cells (i.e. 
Treg) .
12
 
Once produced in the tumor environment, adenosine participates to the generation of an 
immunosuppressed niche favoring the onset of neoplasia, via stimulation of four adenosine 
receptors, named A1, A2A, A2B and A3 (Figure 1), that are widely expressed on several immune cell 
populations.
8
 Adenosine suppresses T cell-mediated anti-tumor immune responses, mainly via A2A 
receptor activation. The inhibition of adenosine-generating enzyme CD73 or the selective blockade 
of A2A receptors have proved to be therapeutically effective in preclinical settings to directly 
improve anti-tumor T cells responses.
13, 14
 Of note, a critical role of this nucleoside is emerging in 
the modulation of MDSC accumulation and functions in the tumor microenvironment 
15, 16
, thus 
providing new insights useful for the development of novel therapeutic approaches, that might help 
to undermine the immune privileged sites where cancer cells grow and proliferate. 
This review is intended to discuss the role of adenosine in shaping myeloid cell biology and 
activity, including tumor-associated macrophages (TAM), dendritic cells (DCs), myeloid-derived 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 W
es
ter
n O
nta
rio
] a
t 0
5:2
9 1
4 J
an
ua
ry
 20
16
 
 4 
 
suppressor cells (MDSCs) and mast cells, that are critical orchestrators of immune responses in the 
tumor microenvironment, pointing out the involvement of this nucleoside in promoting cancer 
progression. 
Adenosine and macrophages 
Macrophages are an integral component of innate immunity, playing a critical role in the 
inflammatory process and host defence. 
8
 These cells infiltrate tissues during inflammation, and 
form polarized populations that perform pro- or anti-inflammatory functions. Tissue resident 
macrophages were previously regarded as differentiated monocytes, which seed the tissues to carry 
out immune sentinel and homeostatic functions.
17
 However, tissue resident macrophages do not 
comprise a homogenous population, but are indeed clusters of different cells with similar functions 
and phenotypes.
17
 Increasing evidences revealed that macrophages differentiate predominantly in 
two major phenotypes, referred to as pro-inflammatory M1-type or anti-inflammatory M2-type, 
depending on tissue microenvironments and/or inflammatory status.
18
 
Within the tumor microenvironment, macrophages are a major stromal component, where they are 
commonly termed tumor-associated macrophages (TAMs), participating both the development of 
malignant tumors and progression of tumor growth.
19
 TAMs exhibit a predominantly M2-like 
phenotype.
8, 20-22
 These cells contribute actively to various processes of cancer growth, such as 
angiogenesis, cell proliferation and metastasis, exerting a local suppression of antitumor 
lymphocyte-mediated immunity, and facilitating matrix deposition and remodeling. 
8, 20-22
 
The adenosine system exerts a plethora of effects on macrophage differentiation, maturation and 
activation.
 23-29 
In particular, this nucleoside exerts inhibitory effects, mediated mainly by A2A 
receptors, on M1 activation.30 Moreover, adenosine, preeminently through A2B receptors and, to a 
lesser extent, via A2A receptors, boosts alternative macrophage activation, as shown by the 
increased expression of several M2 macrophage markers, which include arginase-1, tissue inhibitor 
of matrix metalloproteinase-1 and macrophage galactose-type C-type lectin-1.
31
 In addition, 
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adenosine can support angiogenesis, stimulating vascular endothelial growth factor (VEGF) 
production by macrophages through the stimulation of A2A receptors (Figure 2). 
32-34
 
Recently, Bergamin et al.
35
 evaluated the activity of a glioma-conditioned medium on macrophage 
differentiation, investigating the involvement of adenosine in the release of pro- and anti-
inflammatory cytokines by these cells. Under these conditions, macrophages were polarized toward 
a M2-like phenotype and the in vitro treatment with exogenous adenosine elicited an increase in the 
release of the pro-tumoral cytokine monocyte chemoattractant protein (MCP)-1 via A2A receptors 
(Figure 2). In addition, recent studies displayed that A2A receptors can enhance IL-1  production
36, 
37
. In this regard, it is possible to speculate a role of this receptor subtype in sustain tumor growth 
since it has been reported a role of this pro-inflammatory cytokine in promoting cancer 
development inducing several angiogenic factors from tumor and stromal cells
38
. 
Adenosine and dendritic cells 
Dendritic cells (DCs) are the most potent antigen-presenting cells, that drive the activation and 
differentiation of T cells. Upon exposure to antigens, DCs migrate into proximal lymph nodes. 
Hence, DCs acquire high expression levels of major histocompatibility complex (MHC) class II and 
co-stimulatory molecules, such as CD80/86, CD40, and secrete pro-inflammatory cytokines, such 
as interleukin (IL)-12 and TNF.
39
 This process is known as maturation process. Mature and 
activated DCs polarize T cells toward Th-1 like cells.
39
 Notably, the differentiation and maturation 
process of DCs is context-dependent and it can be affected by the local milieu, generating in turn 
DC subsets with immune- stimulatory or immune-suppressive properties.
40, 41
 Multiple soluble 
factors may influence the expression of co-stimulatory molecules on DCs and the production of 
cytokines, that are essential for their function as antigen-presenting cells. In the absence of co-
stimulatory molecules, instead of promoting immune activation, expansion and function of T cells, 
DCs induce tolerance.
42, 43
 Tolerogenic DCs produce anti-inflammatory cytokines such as IL-10; 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 W
es
ter
n O
nta
rio
] a
t 0
5:2
9 1
4 J
an
ua
ry
 20
16
 
 6 
 
they also express negative costimulatory molecules, including PD-1, B7-H1 and ICOS, that 
contribute to induce T cell anergy, T cell death or Treg expansion.
43
 
Adenosine has been recognized as an important modulator of DC functions. A number of studies 
indicate that adenosine can significantly affect both the activation/maturation process of DCs as 
well as cytokine production. The role of adenosine in regulating DCs functions was first described 
in vitro by Panther et al. 
44, 45
 These authors showed that adenosine enhances the migration of 
human monocyte-derived immature DCs via A1 and A3 activation
44
, and inhibits IL-12 and TNF- 
production in mature DCs via A2A activation 
44, 45
, pointing out a critical role of adenosine in the 
down-regulation of inflammation and protection from tissue damage.
46
 Adenosine can also enhance 
IL-10 and CCL17 release from mature DCs, while it inhibits CXCL-10 
35
, which is implicated in 
the activation of Th1 immune response.
47
 The concomitant presence of IL-10 producing DCs with 
low levels of IL-12 and CCL17 within the tumor microenvironment is related to the accumulation 
of Tregs. 
43, 48, 49
 Therefore, adenosine-conditioned DCs display a reduced capacity of inducing the 
Th1 polarization of CD4
+
T cells, and they fail to prime also CD8
+
T cells in vitro in a cAMP-
dependent manner 
50
. Similar results were observed from Schnurr et al.
51
 in human plasmacitoid 
dendritic cells (pDCs), a subset of IFN type I-producing dendritic cells, that regulate immune 
responses during viral infections, autoimmunity and cancer.
52
 In particular, this study highlighted a 
dual role for adenosine on human pDC function: (i) adenosine induces chemotaxis of immature 
pDCs to inflammatory sites via A1 receptors, which are the dominant receptor subtypes expressed in 
these cells; (ii) during inflammation mature pDCs express high levels of A2A receptors as in mature 
monocyte-derived DCs 
44, 53
; (iii) A2A receptor activation inhibits the pDC-derived cytokines release 
(IL-12, IL-6). 
51
 
Subsequent, later extensive studies have been performed on murine bone-marrow derived DC 
(BMDC) as well as on human monocyte-derived DCs, showing that adenosine-mediated effects on 
the expression of maturation markers and cytokine release from DCs depend on A2B receptor 
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activation.
54, 55
 Notably, these studies clearly indicate that adenosine induces an aberrant 
differentiation of DC precursor cells into a tolerogenic DC subset that produce VEGF, IL-8, IL-10, 
IL-6, transforming growth factor (TGF)- indoleamine 2,3-dioxygenase (IDO) and ariginase-2.54, 56 
The work by Novitskiy et al.
56
 provided the first in vivo evidence on the role of A2B-stimulated DCs 
in promoting tumor growth when injected into mice. The pharmacological blockade of A2B 
receptors in tumor-bearing hosts induced a potent anti-tumor T cell-mediated immune response, by 
enhancing CD11b negative DC activation at the primary tumor site.
34
 Conversely, in a mouse model 
of tumor metastasis, activation of A2B receptors does not appear to influence the percentage of 
myeloid cells, including DCs, nor their maturation/activation status.
57, 58
 This may probably reflect a 
different role of A2B receptors in promoting tumor growth or metastasis. 
In conclusion, adenosine, through the A2A/A2B receptor axis can induce a defective functional 
differentiation of DCs toward a phenotype with pro-angiogenic and tolerogenic features, which 
allows tumor to escape immune surveillance (Figure 2). 
Adenosine and myeloid-derived suppressor cells 
Myeloid-derived suppressor cells (MDSCs) comprise a heterogeneous population of immature 
myeloid cells with regulatory behavior. In cancer settings, tumor-associated factors, including 
inflammatory mediators and growth factors, skew the differentiation of immature myeloid 
progenitor cells into suppressive cells (MDSCs) rather than into mature dendritic cells, 
macrophages and granulocytes.
59, 60
 Once produced, MDSCs accumulate in the peripheral blood, 
lymphoid organs and tumor tissue in animal tumor models as well as in cancer patients.
49, 61, 62
 In 
mouse, MDSCs are identified as CD11b positive Gr1 positive cells (CD11b
+
Gr1
+
 cells)
53, 54, 55
. In 
humans the MDSCs are difficult to identify, although they are commonly positive to CD11b and 
CD33 antigens, and negative to HLA-DR and LIN molecules
53, 54, 55
. MDSCs, together with Tregs, 
represent key regulatory cells contributing to induce immunosuppression and/or angiogenesis in the 
tumor environment.
63, 64
 MDSCs suppress T-cell responses by producing arginase, reactive nitrogen 
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and oxide species and suppressive cytokines. Within tumor lesions MDSCs produce also pro-
angiogenic factors as well as proteases that endorse angiogenesis and metastases. 
Emerging evidence shows that adenosine and its receptor pathways can control some aspects of 
MDSCs biology in the tumor microenvironment. MDSCs express high levels of CD39/CD73 in 
tumor lesions of some murine tumor models, including ret transgenic mice 
15, 65, 66
 , thereby 
contributing to the release of adenosine in the extracellular compartments. The expression of 
adenosine-generating enzymes and possibly the expression of adenosine receptors in MDSCs within 
tumor tissue might be regulated by hypoxia and chronic inflammatory factors, like in tumor cells, 
stromal cells or other immune cell populations of neoplastic lesions. For example, TGF- can 
induce the expression of CD39 and CD73 on myeloid suppressor cells. 
66
 Therefore MDSCs 
produce extracellular adenosine within tumor lesions as an additional mechanism to exacerbate 
immune-suppression (Figure 2). Notably adenosine can also influence the accumulation of MDSCs 
within tumors lesions (Figure 2). Experiments performed in vitro on bone-marrow hematopoietic 
cells have indeed shown that A2B receptor stimulation prevents the differentiation of hematopoietic 
progenitor cells into mature myeloid cells, leading to an accumulation of immature cells with 
immunosuppressive features.
15, 56
 A2B receptor deficiency in Lewis lung carcinoma-bearing mice 
correlates with both a low number of tumor-infiltrating MDSCs and reduced levels of intratumoral 
VEGF.
15
 We have recently demonstrated that the blockade of A2B receptors with a selective 
antagonist reduces significantly the number of tumor-infiltrating MDSCs, inhibits tumor 
angiogenesis and thereby improves T cell-mediated immune surveillance in a melanoma model.
16, 
67, 68
 However, despite the relevance of these observations in the mouse model, future studies are 
needed to provide a more detailed understanding of the impact of adenosine and their receptors on 
MDSCs biology in human cancer environments. 
Adenosine and mast cells 
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Over the years, an increasing number of studies, aimed at defining the involvement of mast cells in 
tumor immunity, have revealed a dual role played by these cells in the tumorigenic process, 
displaying a stimulatory and inhibitory effect on cancer growth based on local stromal conditions.
69,
 
70
 Indeed, mast cells, once recruited into the cancer milieu via tumor-derived chemoattractants [i.e. 
MCP-1, RANTES and stem cell factor (SCF)], are able to selectively secrete pro-tumorigenic 
factors, such as growth factors, histamine, pro-angiogenic factors (i.e. heparin, VEGF and IL-8), as 
well as proteases that endorse angiogenesis and metastases. 
69
 By contrast, these cells can 
counteract the onset of neoplasia, secreting molecules that promote apoptosis (IL-4 and TNF), as 
well as the pro-inflammatory cytokines IL-1 and IL-6, or tryptase, that is able to stimulate protease-
activated receptor-induced inflammation, thus stemming the metastatic processes.
69
 Of note, it has 
been recognized that tumor-infiltrating mast cells participate actively to the remodeling of tumor 
microenvironment as well as to the promotion of tumor growth.
71-73
 Mast cell infiltration and 
activation in tumors were found to be mediated by the tumor-derived stem cell factor (SCF) and its 
receptor c-Kit on mast cells. In these settings, tumor-infiltrating mast cells, upon stimulation by 
high concentrations of SCF, express multiple proinflammatory factors and increase IL-17 
expression in cancers.
71
 In particular, the presence of mast cells promote the infiltration of tumor 
microenvironment by MDSCs and their production of IL-17. MDSC-derived IL-17 then indirectly 
attract Treg cells, increasing their suppressor function and inducing IL-9 production by Treg cells.
72, 
73
 In turn, the release of IL-9 strengthen the survival and pro-tumorigenic action of mast cells within 
the tumor microenvironment.
72
 In this context, SCF-activated mast cells exacerbated also tumor 
immunosuppression by releasing adenosine and increasing Treg cells expansion and activity, with a 
consequent suppression of T cell and NK cells in tumors.
71
 
In vivo studies have shown an adenosine-induced mast cell activation.
74-78
 In particular, set of 
investigations revealed an involvement of A1, A2B, and A3 receptors in the control of these 
proinflammatory actions on mast cells.
 75, 79- 84
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Nowadays, the involvement of adenosine in the regulation of mast cell maturation and 
differentiation within the neoplastic microenvironment remains scarcely examined, and deserves 
more focused investigations. However, available data rise the concept that mast cells comprise a 
highly heterogeneous cell population. Indeed, these cells originate in bone marrow, but mature in 
peripheral organs where they acquire different phenotypic properties after differentiation in the 
local milieu, which may differ among tissues. It is possible that the microenvironment conditions 
where the mast cell reside conditionates the adenosine receptor expression and function, accounting 
for the differences in the receptor actions observed among the studies. In this regard, it has been 
observed that the incubation of human mast cells with the pro-inflammatory cytokines IL-4 or IL-13 
for 6 h induced the expression of A2A and A2B adenosine receptors. By contrast, a prolonged 
stimulation with IL-4 or IL-13 reduced the A2A, but not A2B, receptor expression along with an 
increase in histamine levels.
85
 
Despite the increasing understanding of the contribution of the adenosine system in orchestrating 
the activity of immune cells in cancer microenvironments, the picture is far from being complete 
and several outstanding questions remain unanswered. For example, given the critical role of 
adenosine in conditioning the mast cell activity, what is the differential role of adenosine receptors 
in regulating the release of pro- and anti-tumorigenic mediators released from mast cells? What is 
the role of adenosine in regulating the interplay between mast cells tumor stroma? 
Conclusions and future directions 
Several lines of evidence suggests that adenosine, a soluble factor released in highly expressing-
CD73 tumors, induces pro-tumor effects, including immunosuppression and angiogenesis. The 
adenosine-mediated effects result from the activation of adenosine receptor subtypes (A1, A2A, A2B 
and A3) on a variety of cell components within tumor microenvironment. In the myeloid 
compartment adenosine enhances the immunosuppressive activity of TAM and skews the 
differentiation of DCs into tolerogenic and immunosuppressive DCs. Recent findings support also a 
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critical role of adenosine in the accumulation of MDSCs within tumor environment. These 
properties create and sustain a condition of immunosuppression within the tumor 
microenvironment, with significant suppressive consequences on CD4
+
 and CD8
+
 T-cell effector 
functions. It is well appreciated that, in the tumor microenvironment, adenosine inhibits directly T 
cell–mediated anti-tumor responses and induces Treg mainly via A2A activation.
14, 86
 Compelling 
preclinical evidence has shown that targeting the signaling, with selective adenosine receptor 
antagonists (i.e. A2A/A2B receptors) or inhibitors of adenosine-generating enzymes (i.e. CD73) 
might have a therapeutic potential to boost anti-tumor immune responses, thus limiting tumor 
growth and invasion (reviewed in 
87
 and in 
13
). Accordingly, therapies targeting the adenosine 
inhibitory pathway could have a great impact on tumor microenvironment. On one hand, the 
blockade of the A2 receptor axis can counteract the adenosine- mediated inhibitory effects on 
cytotoxic lymphocyte responses. On the other hand, it appears that these strategies could ameliorate 
the myeloid cell responses that initiate, coordinate and support anti-tumor immune responses. In 
this regards, studies using a tumor model in mice with a myeloid-selective deletion of Adora2a have 
shown that the expression of IL-12 and MHC class II on TAM is increased, while IL-10 production 
by TAM, DCs and MDSCs is reduced.
88
 This effect was associated with improved NK and CD8
+
T 
cell activities.
88
 
Although currently available knowledge indicate that adenosine plays a critical role in regulating 
several aspects of myeloid cells within tumor microenvironment, it would be of interest to 
investigate thoroughly the mechanisms by which the pathway of adenosine and its receptors could 
regulate immune cell functions at the tumor site. For example, the effects of adenosine on mast cells 
in the tumor microenvironment are not well described and deserve more focused studies. An 
important issue to address is how adenosine cooperates with other soluble factors to affect different 
cells within the tumor microenvironment. In addition, it is crucial to evaluate the role of adenosine 
in regulating the interplay between stroma cells and tumor-infiltrating immune cells. 
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Since the effects of adenosine appear to be dependent on the cell types well as on the adenosine 
receptor subtypes distribution and expression, differences in adenosine signaling among the species 
(i.e. rodent versus human species) can occur. Therefore, understanding the relative role of 
adenosine pathway in the context of cancer patients is of critical importance. Future research will 
thus be essential to address the therapeutic potential of the pharmacological tools targeting 
adenosine system for clinical development, both alone and in combination with immune checkpoint 
inhibitors. 
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Figure 1. Schematic diagram illustrating adenosinergic pathways. ATP is released into the 
extracellular environment, which is followed by its sequential degradation to AMP by the cell 
surface enzyme CD39 or alternatively via Nucleotide Pyrophosphatase/Phosphodiesterase 
(NPP), and to adenosine by CD73. Adenosine can also be generated intracellularly from AMP or 
S-adenosylhomocysteine, and then released into the extracellular space via nucleoside 
transporters (NTs). In addition, another source of adenosine is the extracellular NAD
+
 that once 
converted by the CD38 ectoenzyme into ADPribose (ADPR), can be further split by CD203a to 
form AMP and subsequently converted into adenosine by CD73.Extracellular adenosine can 
bind to 4 different G-protein-coupled receptors that either stimulate (A2A and A2B) or inhibit (A1 
and A3) adenylyl cyclase activity and cAMP production in the cell. Furthermore, all adenosine 
receptors couple to mitogen-activated protein kinase (MAPK) pathways, including extracellular 
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signal-regulated kinase 1/2 and p38 MAPK. In the extracellular space, adenosine concentrations 
are controlled by the adenosine deaminase (ADA), which catalyzes its conversion into inosine as 
well as by the activity of nucleoside transporters (NT). Nucleoside transporters, also mediate 
uptake of extracellular adenosine. After intracellular uptake, adenosine undergoes rapid 
phosphorylation to AMP by adenosine kinase, or deamination to inosine by adenosine deaminase 
(ADA). ADA: adenosine deaminase; AK: adenosine kinase; AMP: adenosine monophosphate; 
ATP: adenosine triphosphate; NT: nucleoside transporter. 
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Figure 2. Tumor-promoting effects of adenosine. Adenosine is either produced by tumor cells 
and/or by tumor-infiltrating cells, including MDSC and Treg. Adenosine promotes polarization of 
myeloid cells toward immunosuppressive and pro-angiogenic phenotypes, that prevent T cell 
activation and function. In addition, adenosine inhibits anti-tumor immune response by acting 
directly on effector T cells. These effects contribute to establish a tolerogenic environment, that 
facilitates tumor growth and invasion. DC: dendritic cell; TAM: tumor-associated macrophage; 
MDSC: myeloid-derived suppressor cell; Treg: regulatory T cell; CTL: cytotoxic T lymphocyte; 
VEGF: vascular endothelial growth factor; IL: interleukin; TGF-β: transforming growth factor-β; 
IDO: indolamine 2, 3-dioxygenase; MHC: major histocompatibility complex. 
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